Merck Receives FDA Breakthrough Therapy Designation for Investigational Lung Cancer Treatment

By Yahoo! Finance   |   1 year ago
Merck Receives FDA Breakthrough Therapy Designation for Investigational Lung Cancer Treatment

Merck's sacituzumab tirumotecan (sac-TMT) designated Breakthrough Therapy by FDA for advanced NSCLC with EGFR mutations. The novel drug combination targets TROP2, showing promise in treating various malignancies.

Read More

Did you find this insightful?